Skip to Content Facebook Feature Image

Accenture to Acquire Faculty to Scale AI Capabilities

Business

Accenture to Acquire Faculty to Scale AI Capabilities
Business

Business

Accenture to Acquire Faculty to Scale AI Capabilities

2026-01-06 18:32 Last Updated At:18:52

LONDON--(BUSINESS WIRE)--Jan 6, 2026--

Accenture (NYSE: ACN) has agreed to acquire Faculty, a leading UK-based AI native services and products business built on highly technical applied AI skills and a unique decision intelligence product that features advanced simulation and optimization capabilities. The acquisition will expand Accenture’s capabilities to help its clients reinvent core and critical business processes with safe and secure AI solutions that result in tangible outcomes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105193357/en/

Founded in 2014, Faculty has a strong track record working with public and private sector clients to deploy AI solutions in the U.K. and other key markets. Its services—which include AI strategy, AI safety and the design, build and implementation of high performance AI systems—support the scaled and safe adoption of AI by client organizations.

With a longstanding commitment to AI safety, Faculty works with clients to build AI systems that are safe and ethical by design—addressing risks such as bias, privacy and unexplainable outcomes by ensuring that AI safety is embedded within every stage of the development lifecycle from development, validation and predictions to monitoring. Faculty works with some of the world’s leading AI labs, including OpenAI and Anthropic, to ensure that AI models are safe, as well as with the UK AI Security Institute and other organizations to make baseline safety assessments of general-purpose models.

Upon closing of the transaction, Faculty’s team of more than 400 AI native professionals, including highly qualified data scientists and AI engineers, will integrate with Accenture’s teams to scale world‑class AI capabilities for clients. And, in addition to his role as CEO of Faculty, Marc Warner will become chief technology officer of Accenture and join the company’s Global Management Committee. Before founding Faculty, Warner was a Research Fellow in Quantum Physics at Harvard and served on the court of Imperial College London and as a member of the U.K.’s AI Council, an independent expert committee that provides advice to government and high-level leadership of the Artificial Intelligence (AI) ecosystem.

“With Faculty, we will further accelerate our strategy to bring trusted, advanced AI to the heart of our clients’ businesses,” said Julie Sweet, chair and CEO, Accenture. “I’m pleased to welcome the Faculty team to Accenture and look forward to Marc's contribution shaping our technology vision and strategy as Chief Technology Officer."

As part of the acquisition integration, Faculty Frontier TM, Faculty’s enterprise decision intelligence product, will join Accenture’s suite of products that help organizations make better, faster decisions by connecting data, AI models and business processes into a unified decision system. For example, Accenture and Faculty are already working together to support leading life sciences companies, such as Novartis, to use Frontier TM to transform the economics of clinical trial planning and execution.

Marc Warner, CEO of Faculty, said, “Our vision has always been a world in which safe AI delivers widespread benefits to humanity. We have spent the last ten years supporting our clients to bring this world about, step by step. As AI advances rapidly, the ambition of our clients is now, rightly, no less than the reinvention of their business. I am delighted that by teaming up with Accenture, we have everything in place to support AI transformation from start to finish.”

Faculty is known for its ability to apply AI in mission-critical settings. For example, during the COVID-19 pandemic, Faculty built the UK National Health Service’s (NHS) Early Warning System. This was used daily by NHS Gold Command to accurately predict patient demand across the country, and to optimally allocate critical care resources to where they were needed most.

Manish Sharma, chief strategy and services officer at Accenture, added, “Accenture bridges the best of technology and human ingenuity to maximize returns on AI investments. Together with Faculty we will assemble a powerhouse of talent helping clients make AI work in the real world—linking data, processes, and people so value shows up faster, orchestrated through multiple combinations of bespoke client specific solutions, partner solutions and Faculty Frontier TM. This will help our clients stay competitive, pursue sovereign solutions, and reinvent their operations with transparency and resilience at a critical time.”

Accenture will leverage Faculty’s Fellowship Program, a highly structured early career training and placement program that helps promising STEM PhD and master’s graduates as well as post-doctoral researchers transition from academia to industry. Building on the success of this program in the U.K., Accenture plans to extend the program globally to its people as well as to clients.

Accenture and Faculty have collaborated since December 2023 when Accenture was confirmed as a preferred implementation partner for Faculty Frontier TM.

Completion of the acquisition is subject to customary closing conditions, including required regulatory approval. Terms of the transaction were not disclosed.

Forward-Looking Statements

Except for the historical information and discussions contained herein, statements in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “should,” “likely,” “anticipates,” “aspires,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “positioned,” “outlook,” “goal,” “target” and similar expressions are used to identify these forward-looking statements. These statements are not guarantees of future performance nor promises that goals or targets will be met, and involve a number of risks, uncertainties and other factors that are difficult to predict and could cause actual results to differ materially from those expressed or implied. These risks include, without limitation, risks that: Accenture and Faculty will not be able to close the transaction in the time period anticipated, or at all, which is dependent on the parties’ ability to satisfy certain closing conditions; the transaction might not achieve the anticipated benefits for Accenture; Accenture’s results of operations have been, and may in the future be, adversely affected by volatile, negative or uncertain economic and geopolitical conditions and the effects of these conditions on the company’s clients’ businesses and levels of business activity; Accenture’s business depends on generating and maintaining client demand for the company’s services and solutions including through the adaptation and expansion of its services and solutions in response to ongoing changes in technology and offerings, and a significant reduction in such demand or an inability to respond to the evolving technological environment could materially affect the company’s results of operations; risks and uncertainties related to the development and use of AI could harm the company’s business, damage its reputation or give rise to legal or regulatory action; if Accenture is unable to match people and their skills with client demand around the world and attract and retain professionals with strong leadership skills, the company’s business, the utilization rate of the company’s professionals and the company’s results of operations may be materially adversely affected; Accenture faces legal, reputational and financial risks from any failure to protect client and/or company data from security incidents or cyberattacks; the markets in which Accenture operates are highly competitive, and Accenture might not be able to compete effectively; Accenture’s ability to attract and retain business and employees may depend on its reputation in the marketplace; if Accenture does not successfully manage and develop its relationships with key ecosystem partners or fails to anticipate and establish new alliances in new technologies, the company’s results of operations could be adversely affected; Accenture’s profitability could materially suffer due to pricing pressure, if the company is unable to remain competitive, if its cost-management strategies are unsuccessful or if it experiences delivery inefficiencies or fail to satisfy certain agreed-upon targets or specific service levels; changes in Accenture’s level of taxes, as well as audits, investigations and tax proceedings, or changes in tax laws or in their interpretation or enforcement, could have a material adverse effect on the company’s effective tax rate, results of operations, cash flows and financial condition; Accenture’s results of operations could be materially adversely affected by fluctuations in foreign currency exchange rates; Accenture’s debt obligations could adversely affect its business and financial condition; changes to accounting standards or in the estimates and assumptions Accenture makes in connection with the preparation of its consolidated financial statements could adversely affect its financial results; as a result of Accenture’s geographically diverse operations and strategy to continue to grow in key markets around the world, the company is more susceptible to certain risks; if Accenture is unable to manage the organizational challenges associated with its size, the company might be unable to achieve its business objectives; Accenture might not be successful at acquiring, investing in or integrating businesses, entering into joint ventures or divesting businesses; Accenture’s business could be materially adversely affected if the company incurs legal liability; Accenture’s work with government clients exposes the company to additional risks inherent in the government contracting environment; Accenture’s global operations expose the company to numerous and sometimes conflicting legal and regulatory requirements; if Accenture is unable to protect or enforce its intellectual property rights or if Accenture’s services or solutions infringe upon the intellectual property rights of others or the company loses its ability to utilize the intellectual property of others, its business could be adversely affected; Accenture may be subject to criticism and negative publicity related to its incorporation in Ireland; as well as the risks, uncertainties and other factors discussed under the “Risk Factors” heading in Accenture plc’s most recent Annual Report on Form 10-K, as updated in Item 1A, “Risk Factors” in its Quarterly Report on Form 10-Q for the second quarter of fiscal 2025, and other documents filed with or furnished to the Securities and Exchange Commission. Statements in this news release speak only as of the date they were made, and Accenture undertakes no duty to update any forward-looking statements made in this news release or to conform such statements to actual results or changes in Accenture’s expectations.

About Accenture

Accenture is a leading solutions and services company that helps the world’s leading enterprises reinvent by building their digital core and unleashing the power of AI to create value at speed across the enterprise, bringing together the talent of our approximately 784,000 people, our proprietary assets and platforms, and deep ecosystem relationships. Our strategy is to be the reinvention partner of choice for our clients and to be the most client-focused, AI-enabled, great place to work in the world. Through our Reinvention Services we bring together our capabilities across strategy, consulting, technology, operations, Song and Industry X with our deep industry expertise to create and deliver solutions and services for our clients. Our purpose is to deliver on the promise of technology and human ingenuity, and we measure our success by the 360° value we create for all our stakeholders. Visit us at accenture.com.

Accenture has agreed to acquire Faculty, a leading UK-based AI native services and products business built on highly technical applied AI skills and a unique decision intelligence product that features advanced simulation and optimization capabilities.

Accenture has agreed to acquire Faculty, a leading UK-based AI native services and products business built on highly technical applied AI skills and a unique decision intelligence product that features advanced simulation and optimization capabilities.

SAN DIEGO--(BUSINESS WIRE)--Jan 7, 2026--

Pioneering medical technology company Xenco Medical today announced the expansion of its international distribution hubs across the United Arab Emirates, the Kingdom of Saudi Arabia, Singapore, and the Sultanate of Oman, marking a significant milestone in the company’s mission to deliver advanced surgical solutions to healthcare systems around the world. The strategic expansion strengthens Xenco Medical’s presence across key global healthcare markets, bringing its next-generation biomimetic implants, regenerative biomaterials, and composite polymer surgical technologies to leading hospitals and surgeons throughout the Middle East and Southeast Asia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107117557/en/

Through its newly established regional partnerships, Xenco Medical will support a growing number of orthopedic and surgical centers with its comprehensive portfolio of logistics-optimized, single-use implant and instrument systems designed to enhance procedural efficiency, reduce hospital overhead, and improve patient outcomes. The expansion reflects accelerating global demand for Xenco Medical’s innovative technologies that integrate regenerative science, advanced materials, and AI-driven software to redefine the continuum of surgical care.

“A testament to the universal resonance of our breakthrough technologies, we have been immensely excited by the enthusiastic embrace of Xenco Medical across global markets, demonstrating the ability of scientific advancements to traverse continents. We look forward to translating our growing presence in the Middle East and Southeast Asia into transformative patient outcomes,” said Xenco Medical Founder and CEO Jason Haider.

Inspired by the principles of mechanotransduction, Xenco Medical’s proprietary TrabeculeX Continuum platform harmonizes regenerative biomaterials with AI-powered post-surgical rehabilitation, enabling clinicians to monitor pain scores, patient adherence, and motion recovery through remote, AI-driven pose assessment. The introduction of this integrated ecosystem into new international markets underscores Xenco Medical’s commitment to advancing value-based healthcare worldwide.

The Middle East and Southeast Asia represent some of the fastest-growing healthcare markets globally, driven by investments in hospital infrastructure, medical tourism, and digital health transformation. Xenco Medical’s expansion into these regions positions the company to support these evolving healthcare ecosystems with scalable, sustainable, and clinically differentiated solutions that reduce waste, streamline logistics, and elevate the standard of surgical care. With its logistics-optimized, single-use implant systems eliminating the need for sterilization and reprocessing between procedures, Xenco Medical’s technologies significantly reduce surgical turnover times while improving consistency and safety in operating rooms. These advantages are expected to deliver immediate operational and economic value to healthcare facilities across the newly established Xenco Medical distribution hubs.

As Xenco Medical continues to rapidly grow its global footprint, the company remains focused on translating the promise of biomimetic implants, regenerative medicine, and artificial intelligence into meaningful outcomes for patients and providers alike, bringing its vision of a more longitudinally connected, efficient, and patient-centered surgical ecosystem to healthcare systems around the world. In recognition of its commitment to delivering breakthroughs in global healthcare, Xenco Medical was named one of the World’s Most Innovative Companies by Fast Company Magazine for the second time in 2025, the winner of the World Economic Forum’s 2025 Award for Excellence in Governance and Leadership for Global Challenges, and the 2025 Medical Device/Diagnostics Company of the Year at the prestigious Trailblazer Awards in New York City.

Xenco Medical has scaled its global distribution hubs to the UAE, Saudi Arabia, Singapore, and Oman.

Xenco Medical has scaled its global distribution hubs to the UAE, Saudi Arabia, Singapore, and Oman.

Recommended Articles